Pfizer begins Phase III clinical trial of mRNA-based influenza vaccine | The Financial Express

Pfizer begins Phase III clinical trial of mRNA-based influenza vaccine

According to the company, the trial is being conducted to evaluate efficacy, safety, tolerability, and immunogenicity of the influenza vaccine.

Pfizer begins Phase III clinical trial of mRNA-based influenza vaccine
In the United States, influenza annually causes 140,000 to 710,000 hospitalizations, 12,000 to 52,000 deaths and about $25 billion in economic loss. (File)

Pfizer Inc. on Wednesday announced that they have initiated the Phase III clinical trial of the company’s quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy adults in the United States.

According to the company, the trial is being conducted to evaluate efficacy, safety, tolerability, and immunogenicity of the influenza vaccine.

“For years, there has been a need to better address the burden of influenza, despite the use of existing seasonal flu vaccines. Our experience with RNA viruses and mRNA technology has given us an even deeper understanding of the opportunity to potentially provide more efficacious vaccines that could further reduce the yearly rates of the severe outcomes of viral diseases like flu, including hospitalization and death. We are excited to start the first Phase 3 efficacy study of an mRNA-based influenza vaccine that could potentially deliver an improved flu vaccine to help address the significant burden of this disease,” said Annaliesa Anderson, Ph.D., Senior Vice President, and Chief Scientific Officer, Vaccine Research and Development, Pfizer in a statement.

ALSO READ | Pfizer seeks OK of updated COVID-19 vaccine booster for fall

According to the company, even when currently available vaccine strains match circulating influenza virus strains well, those vaccines typically confer only 40 percent to 60 percent protection, with even lower protection in years with the poor matching of strains.

“With circulating influenza strains continually changing, predicting the best match for the next season’s vaccine is difficult for global health experts as those strains are chosen more than six months before the start of the influenza season that they target. The flexibility of mRNA technology and its rapid manufacturing could potentially allow better strain matches in future years, and in a pandemic influenza situation, mRNA technology could allow rapid, large-scale manufacturing of vaccines. mRNA-based influenza vaccines require only the genetic sequence of the virus,” the company stated on Wednesday.

In the United States, influenza annually causes 140,000 to 710,000 hospitalizations, 12,000 to 52,000 deaths and about $25 billion in economic loss. The vaccine maker claims that although vaccination remains one of the best ways to help prevent infection and serious illness, racial and ethnic minority communities in the U.S. continue to be vaccinated at lower rates.

ALSO READ | Zenara Pharma launches first generic of Pfizer’s Paxlovid for COVID-19 in India

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Photos
14 Photos
G20 Presidency: Rare Photos from all-party meet, chaired by PM Modi
11 Photos
‘The festival of democracy’ – Modi votes in Gujarat 2nd phase! See PHOTOS
11 Photos
Gujarat Assembly Election 2022: The Festival of Democracy – In PICS